Figure 4.
The pooled PR (A), ORR (B), SDR (C), and DCR (D) in patients with R/R indolent B-NHL receiving copanlisib monotherapy were significantly higher than those in patients with R/R aggressive B-NHL receiving copanlisib monotherapy, while result for pooled PDR (E) was reversed between the two groups.
